Migraine frequency
SE, Migraine, migraine
MIGRAINE, MIGRAINE
Migraine frequency was similar across treatment groups at baseline (~ 14 MMDs). Over the final 4 weeks of the double-blind treatment period (Weeks 21–24), mean (SE) reductions in MMDs were greater in patients that received eptinezumab (−5.6 [0.39] MMDs, 100 mg; −5.7 [0.39] MMDs, 300 mg) than in patients that received placebo (−2.3 [0.50] MMDs, placebo/100 mg and −2.8 [0.50] MMDs, placebo/300 mg) (Supplemental Table 
Change from baseline in monthly migraine days (MMRM; efficacy analysis set).  BL, baseline; Epti, eptinezumab; LS, least squares; MMRM, mixed model for repeated measuresMigraine responder rates are depicted in Fig. 
Patients achieving (